Saturday 17 October 2026
Export IBIO’s income statement to Excel — free account
iBio, Inc.
IBIO Healthcare Biotechnology
In the quarter to June 2026, revenue grew 100.0%, EPS grew 77.4% and free cash flow fell 35.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.77
0.01
−1.28%
Follow IBIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(54.50%) | (70.22%) | (62.09%) | (65.70%) | |
| (45.35%) | (57.47%) | (52.61%) | (54.04%) | ||
ROIC |
(177.64%) | (412.24%) | (660.56%) | 0.00% | |
Return on Tangible Assets |
(41.95%) | (48.59%) | (37.28%) | (39.54%) | |
Average Days of Receivables |
35.15 | — | — | 0.00 | |
Free Cash Flow per Share |
(0.33) | (0.19) | (0.19) | (0.23) | |
Free Cash Flow |
(17.30) | (19.19) | (22.16) | (23.80) | |
Capital Expenditures |
(0.05) | (0.56) | (0.56) | (0.58) | |
| Other line items | |||||
Cash ROIC |
(16.27%) | (17.56%) | (14.55%) | (13.70%) | |
Accounts Receivable Turnover |
0.10 | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,564.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,539.26% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
213.04% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(107.05) | (145.56) | (202.51) | (663.04) | |
Operating CF/Net income |
0.86 | 0.75 | 0.78 | 0.70 | |
Depreciation/Fixed assets |
0.35 | 0.29 | 0.27 | 0.27 | |
Capex/Depreciation |
(0.04) | (0.56) | (0.62) | (0.69) | |
Revenue per Share |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.33) | (0.19) | (0.18) | (0.22) | |
Capex per Share |
0.00 | (0.01) | 0.00 | (0.01) | |
Capex to Sales |
0.07 | 0.00 | 0.00 | 0.00 |
Columns are period end dates